Skip to Main Content

Advertisement

Skip Nav Destination

Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228.

Blood (2007) 110 (11): 474.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement